Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

被引：2
|
作者：
Kienle, D. [1 ]
Winterhalder, R. [2 ]
Koeberle, D. [3 ]
Horber, D. [4 ]
Kueng, M. [5 ]
Saletti, P. [6 ]
Helbling, D. [7 ]
Bastian, S. [8 ]
Dietrich, D. [9 ]
Baertschi, D. [9 ]
Pilop, C. [9 ]
Von Moos, R. [8 ]
机构：
[1] Stadtspital Triemli, Haematol & Med Oncol, Zurich, Switzerland
[2] Kantonsspital Luzern, Med Oncol, Luzern, Switzerland
[3] Claraspital Basel, Oncol, Basel, Switzerland
[4] Kantonsspital St Gallen, Oncol Haematol, St Gallen, Switzerland
[5] HFR, Med Oncol, Fribourg, Switzerland
[6] Oncol Inst Southern Switzerland, Med Oncol, Bellinzona, Switzerland
[7] OnkoZentrum Klin Pk, Oncol, Zurich, Switzerland
[8] Kantonsspital Graubuenden, Oncol Haematol, Chur, Switzerland
[9] Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30565-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1322
引用
收藏
页码：S194 / S195
页数：2
相关论文
共 50 条
  • [31] RESULTS OF THE USE OF OXALIPLATIN AND CAPECITABINE PLUS CETUXIMAB AS FIRST-LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST ANALYSES
    Barroso, S.
    Sanches, E.
    Ferreira, J. M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 148 - 148
  • [32] Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
    Assenat, Eric
    Desseigne, Francoise
    Thezenas, Simon
    Viret, Frederic
    Mineur, Laurent
    Kramar, Andrew
    Samalin, Emmanuelle
    Portales, Fabienne
    Bibeau, Frederic
    Crapez-Lopez, Evelyne
    Bleuse, Jean Pierre
    Ychou, Marc
    ONCOLOGIST, 2011, 16 (11): : 1557 - 1564
  • [33] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Hitoshi Soda
    Hiromichi Maeda
    Junichi Hasegawa
    Takao Takahashi
    Shoichi Hazama
    Mutsumi Fukunaga
    Emiko Kono
    Masahito Kotaka
    Junichi Sakamoto
    Naoki Nagata
    Koji Oba
    Hideyuki Mishima
    BMC Cancer, 15
  • [34] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Soda, Hitoshi
    Maeda, Hiromichi
    Hasegawa, Junichi
    Takahashi, Takao
    Hazama, Shoichi
    Fukunaga, Mutsumi
    Kono, Emiko
    Kotaka, Masahito
    Sakamoto, Junichi
    Nagata, Naoki
    Oba, Koji
    Mishima, Hideyuki
    BMC CANCER, 2015, 15
  • [35] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [36] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Shigenori Kadowaki
    Toshiki Masuishi
    Takashi Ura
    Keiji Sugiyama
    Seiichiro Mitani
    Yukiya Narita
    Hiroya Taniguchi
    Kei Muro
    International Journal of Clinical Oncology, 2021, 26 : 701 - 707
  • [37] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
  • [38] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Kadowaki, Shigenori
    Masuishi, Toshiki
    Ura, Takashi
    Sugiyama, Keiji
    Mitani, Seiichiro
    Narita, Yukiya
    Taniguchi, Hiroya
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (04) : 701 - 707
  • [39] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Geoffrey Y. Ku
    Benjamin A. Haaland
    Gilberto de Lima Lopes
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 231 - 238
  • [40] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 231 - 238
12345